As more NIH cuts loom, researchers warn U.S. science at risk

The signs of crisis in American science are obvious. Billions of dollars in grants have been cancelled or suspended for reasons unrelated to scientific merit, and the ranks of NIH’s scientific leadership have been purged with no explanation. Public funding for research involving mRNA has been stifled and ties to international collaborators cut.

PhRMA’s Board of Directors has explicitly decided to deprioritize efforts to shield NIH as it pursues more immediate goals such as modifying the Medicare drug negotiation program’s treatment of small molecule drugs, a member of the trade association’s board told BioCentury. The scale of the cuts could, however, disrupt ongoing collaborations between NIH and academic researchers and industry, as well as erode the scientific discoveries that are the starting point for biopharmaceutical advances. ...